Extending tranSMART for Meta-Analysis of Genomic Data Across Trials

Haiguo Wu,Elisabeth L Scheufele,D. Aronzon,M. Palchuk

Abstract:

What problem does this paper attempt to address?

Short-term and long-term financial toxicity from breast cancer treatment: a qualitative study

Sandy Lee,Ramona G Olvera,Karen Shiu-Yee,Laura J Rush,Willi L Tarver,Tessa Blevins,Ann Scheck McAlearney,Barbara L Andersen,Electra D Paskett,William E Carson,J C Chen,Samilia Obeng-Gyasi

DOI: https://doi.org/10.1007/s00520-023-08199-z

2023-12-14

Abstract:Purpose: The rising cost of breast cancer treatment has increased patients' financial burden, intensifying an already stressful treatment process. Although researchers increasingly recognize the harmful impact of medical and nonmedical costs associated with cancer treatment, understanding patients' perspectives of financial toxicity is limited. We aimed to explore the topic of financial toxicity through the lived experiences of patients with breast cancer from groups at risk of social and economic marginalization. Methods: We conducted semi-structured interviews with 50 women with breast cancer from four specific groups: Black women, Medicaid enrollees, rural residents, and women age ≤ 40. We transcribed, coded, and analyzed the data using deductive and inductive approaches. Results: Two overarching themes captured patients' experiences of financial toxicity: short-term and long-term impacts. Short-term stressors included direct medical (e.g., co-pays, premiums), nonmedical (e.g., transportation, lodging), and indirect (e.g., job loss, reduced work hours) costs. Early in their treatments, patients' focus on survival took precedence over financial concerns. However, as the treatment course progressed, fear of consequences from compounding costs of care and financial distress negatively impacted patients' lifestyles and outlooks for the future. Conclusion: Programs addressing financial toxicity that look beyond early-phase interventions are needed. Specifically, patients struggling with the accumulation of treatment costs and the resultant stress require ongoing support. Long-term support is especially needed for groups vulnerable to financial instability and social marginalization.
Financial toxicity experienced by patients with breast cancer-related lymphedema: a systematic review

Jingru Bian,Aomei Shen,Wanwan Yang,Liyuan Zhang,Wanmin Qiang

DOI: https://doi.org/10.1007/s00520-023-07800-9

2023-05-27

Abstract:Purpose: To perform a systematic review on financial toxicity of breast cancer-related lymphedema. Methods: Seven databases were searched on September 11, 2022. Eligible studies were identified, analyzed, and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Empirical studies were appraised by the Joanna Briggs Institute (JBI) tools. The Mixed Methods Appraisal Tool version 2018 was used to assess the mixed method studies. Results: A total of 963 articles were identified, but only 7 articles reporting on 6 studies met the eligibility criteria. A 2-year treatment for lymphedema was approximately USD$14,877 to USD$23,167 in America. In Australia, the average out-of-pocket costs ranged from A$207 to A$1400 (USD$156.26 to USD$1056.83) per year. Outpatient visits, compressed clothing, and hospital admissions were the dominant costs. The financial toxicity was associated with the severity of lymphedema, and patients with heavy financial burden had to reduce other expenses or even forgo the treatment. Conclusion: Breast cancer-related lymphedema aggravated the economic burden of patients. The included studies showed great variation in the methods used and therefore differences in cost results. The national government should further improve the healthcare system and increase the insurance coverage of lymphedema treatment to alleviate this burden. More research is needed to focus on financial toxicity experience of breast cancer patients with lymphedema. Implications for cancer survivors: The cost of the ongoing treatment of breast cancer-related lymphedema influences patients' economic situation and quality of life. Survivors need to be informed early about the potential financial burden associated with lymphedema treatment.
Patient-Reported Financial Burden of Treatment for Colon or Rectal Cancer

Sheetal Kircher,Fenghai Duan,Na An,Ilanan F. Gareen,JoRean D. Sicks,Gelareh Sadigh,Jennifer M. Suga,Heather Kehn,Paul T. Mehan,Rajesh Bajaj,David S. Hanson,Samir M. Dalia,Jared D. Acoba,Demet Gokalp Yasar,Elyse R. Park,Lynne I. Wagner,Ruth C. Carlos

DOI: https://doi.org/10.1001/jamanetworkopen.2023.50844

2024-01-10

JAMA Network Open

Abstract:Importance The longitudinal experience of patients is critical to the development of interventions to identify and reduce financial hardship. Objective To evaluate financial hardship over 12 months in patients with newly diagnosed colorectal cancer (CRC) undergoing curative-intent therapy. Design, Setting, and Participants This prospective, longitudinal cohort study was conducted between May 2018 and July 2020, with time points over 12 months. Participants included patients at National Cance Institute Community Oncology Research Program sites. Eligibility criteria included age at least 18 years, newly diagnosed stage I to III CRC, not started chemotherapy and/or radiation, treated with curative intent, and able to speak English. Data were analyzed from December 2022 through April 2023. Main Outcomes and Measures The primary end point was financial hardship, measured using the Comprehensive Score for Financial Toxicity (COST), which assesses the psychological domain of financial hardship (range, 0-44; higher score indicates better financial well-being). Participants completed 30-minute surveys (online or paper) at baseline and 3, 6, and 12 months. Results A total of 450 participants (mean [SD] age, 61.0 [12.0] years; 240 [53.3%] male) completed the baseline survey; 33 participants (7.3%) were Black and 379 participants (84.2%) were White, and 14 participants (3.1%) identified as Hispanic or Latino and 424 participants (94.2%) identified as neither Hispanic nor Latino. There were 192 participants (42.7%) with an annual household income of $60 000 or greater. There was an improvement in financial hardship from diagnosis to 12 months of 0.3 (95% CI, 0.2 to 0.3) points per month ( P < .001). Patients with better quality of life and greater self-efficacy had less financial toxicity. Each 1-unit increase in Functional Assessment of Cancer Therapy–General (rapid version) score was associated with an increase of 0.7 (95% CI, 0.5 to 0.9) points in COST score ( P < .001); each 1-unit increase in self-efficacy associated with an increase of 0.6 (95% CI, 0.2 to 1.0) points in COST score ( P = .006). Patients who lived in areas with lower neighborhood socioeconomic status had greater financial toxicity. Neighborhood deprivation index was associated with a decrease of 0.3 (95% CI, −0.5 to −0.1) points in COST score ( P = .009). Conclusions and Relevance These findings suggest that interventions for financial toxicity in cancer care should focus on counseling to improve self-efficacy and mitigate financial worry and screening for these interventions should include patients at higher risk of financial burden.

medicine, general & internal
The social and economic toll of cancer survivorship: a complex web of financial sacrifice

Matthew P. Banegas,Jennifer L. Schneider,Alison J. Firemark,John F. Dickerson,Erin E. Kent,Janet S. de Moor,Katherine S. Virgo,Gery P. Guy,Donatus U. Ekwueme,Zhiyuan Zheng,Alexandra M. Varga,Lisa A. Waiwaiole,Stephanie M. Nutt,Aditi Narayan,K. Robin Yabroff

DOI: https://doi.org/10.1007/s11764-019-00761-1

2019-05-23

Journal of Cancer Survivorship

Abstract:<h3>Purpose</h3><p>To assess the financial outcomes and associated social and economic effects on cancer survivors and their families.</p><h3>Methods</h3><p>We assessed the responses of 1656 cancer survivors to a survey with both closed- and open-ended questions about cancer-related financial sacrifices they and their family experienced and evaluated differences in financial sacrifice by reported levels of cancer-related debt.</p><h3>Results</h3><p>The most commonly reported financial sacrifices included cutbacks on household budgets, challenges with health care insurance and costs, career/self-advancement constraints, reduction/depletion of assets, and inability to pay bills. Survivors who incurred $10,000 or more in debt were significantly more likely to report social and economic impacts, including housing concerns and strained relationships.</p><h3>Conclusions</h3><p>Our analysis demonstrates both the frequency with which cancer survivors and families must make financial sacrifices as a result of their cancer, and the variety of forms that this sacrifice can take, even for individuals who have health insurance. The many types of financial hardship create challenges that are unique to each survivor and family.</p><h3>Implications for Cancer Survivors</h3><p>Interventions that allow for personalized assistance with the specific financial and social needs of cancer survivors and their families have the potential to address a critical aspect of the long-term wellbeing of this important population.</p>

oncology,social issues
Self-Reported Risk Factors for Financial Distress and Attitudes Regarding Cost Discussions in Cancer Care: A Single-Institution Cross-Sectional Pilot Study of Breast Reconstruction Recipients

Malke Asaad,Chad Bailey,Stefanos Boukovalas,Jun Liu,Mark W Clemens,Jesse Selber,Charles E Butler,Anaeze C Offodile 2nd

DOI: https://doi.org/10.1097/PRS.0000000000007703

2021-04-01

Abstract:Background: High treatment costs associated with breast cancer are a substantial burden to patients and society. Despite mounting awareness, patient perspectives about the value of cost discussions in breast reconstruction and risk factors for financial distress are unknown. Methods: The authors performed a single-institution, cross-sectional survey of all women who underwent breast reconstruction following mastectomy or lumpectomy for breast cancer or risk reduction. Questions were derived from previously published survey items, and the authors leveraged regression analysis to identify patient-level risk factors for major financial distress. Results: A total of 647 of 2293 patients returned the survey questionnaires (28.2 percent response rate). From the 647 respondents, 399 (62 percent) underwent breast reconstruction, and of these, 140 (35 percent) reported that total treatment expenses were higher than expected. One hundred twenty-nine breast reconstruction patients (32 percent) paid over $5000 in out-of-pocket costs. Two hundred eighty-four (71 percent) felt that surgeons should explain the estimated out-of-pocket costs when choosing a type of breast reconstruction and 205 (51 percent) believed that a financial consultation should be scheduled with every new cancer diagnosis. However, only 52 patients (13 percent) reported having had cost discussions with the treatment team. The incidence of major financial distress was n = 70 (18 percent), and following regression analysis, higher credit score and annual income were associated with a 66 percent and 69 percent risk reduction, respectively. Conclusions: Recipients of breast reconstruction demonstrate unanticipated and unplanned financial strain related to out-of-pocket expenses and believe that cost-consciousness should impact treatment decisions. Lower income and credit score are associated with financial distress. Cost discussions may optimize decision-making in preference sensitive conditions.
Ornstein theory

D. Ornstein

DOI: https://doi.org/10.4249/scholarpedia.3957

Scholarpedia

Abstract:
Patient and family financial burden associated with cancer treatment in Canada: a national study

Christopher J. Longo,Margaret I. Fitch,Jonathan M. Loree,Linda E. Carlson,Donna Turner,Winson Y. Cheung,Darin Gopaul,Janet Ellis,Jolie Ringash,Maria Mathews,Jim Wright,Christiaan Stevens,David D’Souza,Robin Urquhart,Tuhin Maity,Fanor Balderrama,Evette Haddad

DOI: https://doi.org/10.1007/s00520-020-05907-x

IF: 3.1

2021-01-05

Supportive Care in Cancer

Abstract:Abstract Goal To determine patient-reported financial and family burden associated with treatment of cancer in the previous 28 days across Canada. Methods A self-administered questionnaire (P-SAFE v7.2.4) was completed by 901 patients with cancer from twenty cancer centres nationally (344 breast, 183 colorectal, 158 lung, 216 prostate) measuring direct and indirect costs related to cancer treatment and foregone care. Monthly self-reported out-of-pocket-costs (OOPCs) included drugs, homecare, homemaking, complementary/ alternative medicines, vitamins/supplements, family care, accommodations, devices, and “other” costs. Travel and parking costs were captured separately. Patients indicated if OOPC, travel, parking, and lost income were a financial burden. Results Mean 28-day OOPCs were CA$518 (US Purchase Price Parity [PPP] $416), plus CA$179 (US PPP $144) for travel and CA$84 (US PPP $67) for parking. Patients self-reporting high financial burden had total OOPCs (33%), of CA$961 (US PPP $772), while low-burden participants (66%) had OOPCs of CA$300 (US PPP $241). “Worst burden” respondents spent a mean of 50.7% of their monthly income on OOPCs (median 20.8%). Among the 29.4% who took time off work, patients averaged 18.0 days off. Among the 26.0% of patients whose caregivers took time off work, caregivers averaged 11.5 days off. Lastly, 41% of all patients had to reduce spending. Fifty-two per cent of those who reduced spending were families earning < CA$50,000/year. Conclusions In our Canadian sample, high levels of financial burden exist for 33% of patients, and the severity of burden is higher for those with lower household incomes.

oncology,health care sciences & services,rehabilitation
Financial cost of lymphedema borne by women with breast cancer

John Boyages,Ying Xu,Senia Kalfa,Louise Koelmeyer,Bonny Parkinson,Helen Mackie,Hector Viveros,Paul Gollan,Lucy Taksa

DOI: https://doi.org/10.1002/pon.4239

Abstract:Objective: Our study examines the financial cost of lymphedema following a diagnosis of breast cancer and addresses a significant knowledge gap regarding the additional impact of lymphedema on breast cancer survivors. Methods: An online national survey was conducted with 361 women who had either breast cancer without lymphedema (BC) (group 1, n = 209) or breast cancer with lymphedema (BC+LE) (group 2, n = 152). Participant recruitment was supported by the Breast Cancer Network Australia and the Australasian Lymphology Association. Results: Both breast cancer and lymphedema result in significant out-of-pocket financial costs borne by women. Of patients with BC+LE, 80% indicated that their breast cancer diagnosis had affected them financially compared with 67% in the BC group (P < .020). For patients with lymphedema, over half (56%) indicated that this specific additional diagnosis to their breast cancer affected them financially and that costs increased with lymphedema severity. The cost of compression garments formed a large proportion of these costs (40.1%). The average number of attendances to a therapist each year was 5.8 (range, 0-45). Twenty-five patients (16.4%) had an episode of cellulitis in the past year. The incidence of cellulitis was 7.7% in 91 patients with subclinical or mild lymphedema compared with 29.5% of 61 patients with more extensive lymphedema (P < .001). The average out-of-pocket financial cost of lymphedema care borne by women was A$977 per annum, ranging from A$207 for subclinical lymphedema to over A$1400 for moderate or severe lymphedema. Conclusions: This study identifies an additional detrimental effect of lymphedema on women in terms of financial costs.
Patient‐reported persistent lymphedema and peripheral neuropathy among long‐term breast cancer survivors in the Carolina Breast Cancer Study

Rina A. Yarosh,Hazel B. Nichols,Qichen Wang,Rachel Hirschey,Erin E. Kent,Lisa A. Carey,Sandra C. Hayes,Adeyemi A. Ogunleye,Melissa A. Troester,Eboneé N. Butler

DOI: https://doi.org/10.1002/cncr.35650

IF: 6.9209

2024-11-24

Cancer

Abstract:Background Improved breast cancer treatment has lengthened survival but also has long‐term impacts. Lymphedema and peripheral neuropathy are treatment‐related sequelae that extend into survivorship. Co‐occurrence of these conditions may further impair functional well‐being. Few studies have estimated the burden of these conditions among diverse survivors. Methods Carolina Breast Cancer Study Phase 3 enrolled survivors diagnosed between 2008 and 2013 in North Carolina. Black and younger women (aged 5 lymph nodes removed, and peripheral neuropathy was higher among women treated with taxane‐based chemotherapy. Co‐occurrence was higher among women with >5 lymph nodes removed (vs. <5; PD, 5.4; 95% CI, 2.1 to 8.8) and those treated with taxane‐based chemotherapy (vs. no chemotherapy; PD, 6.8; 95% CI, 3.9 to 9.7). The burden of lymphedema (PD, 2.7; 95% CI, 0.9 to 6.3) and peripheral neuropathy (PD, 5.8; 95% CI, 1.7 to 9.9) was higher among Black than White women. The prevalence of lymphedema (PD, 1.8; 95% CI, −1.5 to 5.1) and peripheral neuropathy (PD, 4.6; 95% CI, 0.8 to 8.4) was elevated among younger compared to older women. Conclusions Lymphedema and peripheral neuropathy affect a substantial proportion of survivors. Interventions are needed to reduce this burden.

oncology
Diagnostic impression cytology for external eye disease.

S. L. Maskin,K. Heitman,A. W. Lawton,R. Yee

DOI: https://doi.org/10.1097/00003226-198912000-00009

IF: 3.152

1989-12-01

Cornea

Abstract:The authors describe their experience with the use of impression cytology (IC) as a diagnostic aid in the evaluation of external eye disorders. IC is shown to be useful for diagnosis of epithelial cell storage disorders, infectious diseases, and allergic disorders.
Antimicrobial resistance of Staphylococcus pseudintermedius.

K. Kadlec,S. Schwarz

DOI: https://doi.org/10.1111/j.1365-3164.2012.01056.x

2012-08-01

Abstract:Staphylococcus pseudintermedius, Staphylococcus intermedius and Staphylococcus delphini together comprise the S. intermedius group (SIG). Within the SIG, S. pseudintermedius represents the major pathogenic species and is involved in a wide variety of infections, mainly in dogs, but to a lesser degree also in other animal species and humans. Antimicrobial agents are commonly applied to control S. pseudintermedius infections; however, during recent years S. pseudintermedius isolates have been identified that are meticillin-resistant and have also proved to be resistant to most of the antimicrobial agents approved for veterinary applications. This review deals with the genetic basis of antimicrobial resistance properties in S. pseudintermedius and other SIG members. A summary of the known resistance genes and their association with mobile genetic elements is given, as well as an update of the known resistance-mediating mutations. These data show that, in contrast to other staphylococcal species, S. pseudintermedius seems to prefer transposon-borne resistance genes, which are then incorporated into the chromosomal DNA, over plasmid-located resistance genes.
Logistic burdens of cancer care: A qualitative study

Allison C. Dona,Patricia I. Jewett,Sharon Hwee,Katherine Brown,Matia Solomon,Arjun Gupta,Deanna Teoh,Guang Yang,Julian Wolfson,Yingling Fan,Anne H. Blaes,Rachel I. Vogel

DOI: https://doi.org/10.1371/journal.pone.0300852

IF: 3.7

2024-04-04

PLoS ONE

Abstract:Cancer treatment often creates logistic conflicts with everyday life priorities; however, these challenges and how they are subjectively experienced have been largely unaddressed in cancer care. Our goal was to describe time and logistic requirements of cancer care and whether and how they interfered with daily life and well-being. We conducted interviews with 20 adults receiving cancer-directed treatment at a single academic cancer center. We focused on participants’ perception of the time, effort, and energy-intensiveness of cancer care activities, organization of care requirements, and preferences in how to manage the logistic burdens of their cancer care. Participant interview transcripts were analyzed using an inductive thematic analysis approach. Burdens related to travel, appointment schedules, healthcare system navigation, and consequences for relationships had roots both at the system-level (e.g. labs that were chronically delayed, protocol-centered rather than patient-centered bureaucratic requirements) and in individual circumstances (e.g. greater stressors among those working and/or have young children versus those who are retired) that determined subjective burdensomeness, which was highest among patients who experienced multiple sources of burdens simultaneously. Our study illustrates how objective burdens of cancer care translate into subjective burden depending on patient circumstances, emphasizing that to study burdens of care, an exclusive focus on objective measures does not capture the complexity of these issues. The complex interplay between healthcare system factors and individual circumstances points to clinical opportunities, for example helping patients to find ways to meet work and childcare requirements while receiving care.

multidisciplinary sciences
Predictors of financial difficulties and work modifications among cancer survivors in the United States

Robin L Whitney,Janice F Bell,Sarah C Reed,Rebecca Lash,Richard J Bold,Katherine K Kim,Andra Davis,David Copenhaver,Jill G Joseph

DOI: https://doi.org/10.1007/s11764-015-0470-y

Abstract:Purpose: The aim of this study is to examine predictors of cancer-related financial difficulties and work modifications in a national sample of cancer survivors. Methods: Using the 2011 Medical Expenditure Panel Survey and Experiences with Cancer Survivorship Supplement, the prevalence of financial difficulties and work modifications was examined. Logistic regression and survey weights were used to model these outcomes as functions of sociodemographic and health covariates separately among survivors in active treatment and survivors under age 65 years. Results: Among all survivors, 33.2% reported any financial concern, with 17.9% reporting financial difficulties such as debt or bankruptcy. Among working survivors, 44.0% made any work modification and 15.3% made long-term work modifications (e.g., delayed or early retirement). Among those in active treatment, predictors of financial difficulty included: race/ethnicity other than white, non-Hispanic [OR = 8.0; 95% CI 2.2-28.4]; income <200% of federal poverty level (FPL) [OR = 15.7; 95% CI 2.6-95.2] or between 200 and 400% of FPL [OR = 8.2; 95% CI 1.3-51.4]; residence in a non-metropolitan service area [OR = 6.4; 95% CI 1.6-25.0]; and good/fair/poor self-rated health [OR = 3.8; 95% CI 1.0-14.2]. Among survivors under age 65 years, predictors of long-term work modifications included good/fair/poor self-rated health [OR = 4.1; 95% CI 1.6-10.2], being married [OR = 2.2; 95% CI 1.0-4.7], uninsured [OR = 3.5; 95% CI 1.3-9.3], or publicly insured [OR = 9.0; 95% CI 3.3-24.4]. Conclusions: A substantial proportion of cancer survivors experience cancer-related financial difficulties and work modifications, particularly those who report race/ethnicity other than white, non-Hispanic, residence in non-metropolitan areas, worse health status, lower income, and public or no health insurance. Implications for cancer survivors: Attention to the economic impact of cancer treatment is warranted across the survivorship trajectory, with particular attention to subgroups at higher risk.
Patient Perceived Financial Burden in Haematological Malignancies: A Systematic Review.

Catriona Parker,Danielle Berkovic,Darshini Ayton,Ella Zomer,Danny Liew,Andrew Wei

DOI: https://doi.org/10.3390/curroncol29060305

2022-06-24

Current Oncology

Abstract:Advances in scientific understanding have led to novel therapies and improved supportive care for many patients with haematological malignancies. However, these new drugs are often costly, only available at centralised health care facilities, require regular specialist reviews and lengthy treatment regimens. This leads to a significant financial burden. Understanding the impact of financial burden on haematological patients is important to appreciate the urgency of alleviating this systemic issue. Eligible studies were identified by systematically searching Medline, PsycINFO, CINAHL and Embase. Self-reported data reported in both quantitative and qualitative studies that described the financial burden for patients with haematological malignancies were included. Quality appraisal of the included studies was undertaken using the Joanna Briggs Institute tools. A narrative synthesis was employed. For quantitative studies, outcomes were extracted, tabulated and categorised to find similarities and differences between the studies. For qualitative studies, quotations, codes and themes were extracted and then clustered. An inductive approach derived qualitative themes. Twenty studies were identified for inclusion. Of the quantitative studies most (83%) employed un-validated researcher-generated measures to assess financial burden. Between 15-59% of patients experienced a financial burden. Out-of-pocket expenditure was frequent for clinical appointments, prescription and non-prescription medication, and travel. Financial burden was associated with a worsening quality of life and living in metropolitan areas, but there was no evidence for impact on survival. Patient-centred experiences from the qualitative inquiry complemented the quantitative findings and five themes were determined: familial or household impact; reliance on others; barriers to care due to cost; and barriers to accessing financial assistance and sources of out-of-pocket expenses. The impacts of financial burden are yet to be fully appreciated in haematological malignancies, exacerbated by the heterogeneous methods employed by researchers. Future work should focus on identifying the long-term ramifications of financial burden for patients and should trial interventions to reduce its prevalence and patient impacts.

oncology
The need for online information on the economic consequences of cancer diagnosis, treatment, and survivorship

Cathy J Bradley

DOI: https://doi.org/10.2196/jmir.7.3.e29

2005-07-01

Abstract:The Internet is commonly used to provide treatment information to patients diagnosed with cancer. Notably missing from the existing websites is information on the cost of cancer care in terms of medical costs to the patient and work-related consequences. The purpose of this paper is to describe what is known about the economic cost of cancer and to describe how this information can be structured so that it is of more benefit to patients. This paper first provides an overview of the information available regarding medical expenses and productivity costs associated with cancer survivorship, particularly with respect to cancer and employment. Second, it draws attention to the sparse economic information available online to cancer survivors. Patients can find information on sources of financial assistance, but they cannot estimate from the available information the cost of their care or anticipate the impact that cancer and its treatment may have on their jobs. Finally, a strategy for filling the void in online economic cancer information is described. Substantial opportunity exists to provide economic information to cancer patients and their families. The Internet is a natural forum for gathering and disseminating economic information. A unique advantage of the Internet is its ability to put information immediately in the hands of cancer patients and their families--assisting them to become informed consumers and skilled negotiators.
Financial Toxicity in Breast Reconstruction: The Role of the Surgeon-Patient Cost-of-Care Discussion

Brigit D. Baglien,Nishant Ganesh Kumar,Nicholas L. Berlin,Sarah T. Hawley,Reshma Jagsi,Adeyiza O. Momoh

DOI: https://doi.org/10.1055/s-0043-1778040

2024-01-20

Seminars in Plastic Surgery

Abstract:The financial burden of breast cancer treatment and reconstruction is a significant concern for patients. Patient desire for preoperative cost-of-care counseling while navigating the reconstructive process remains unknown. A cross-sectional survey of women from the Love Research Army was conducted. An electronic survey was distributed to women over 18 years of age and at least 1 year after postmastectomy breast reconstruction. Descriptive statistics and multivariable modeling were used to determine desire for and occurrence of cost-of-care discussions, and factors associated with preference for such discussions. Secondary outcomes included the association of financial toxicity with desire for cost discussions. Among 839 women who responded, 620 women (74.1%) did not speak to their plastic surgeon and 480 (57.4%) did not speak to a staff member regarding costs of breast reconstruction. Of the 550 women who reported it would have been helpful to discuss costs, 315 (57.3%) were not engaged in a financial conversation initiated by a health care provider. A greater proportion of women who reported financial toxicity, compared to those who did not, would have preferred to discuss costs with their plastic surgeon (65.2% vs. 43.5%, p < 0.001) or a staff member (75.5% vs. 59.3%, p < 0.001). Among women with financial toxicity, those who had some form of insurance (private, Medicaid, Medicare, "other") were significantly more likely to prefer a cost-of-care discussion ( p < 0.001, p = 0.02, p = 0.05, p = 0.01). Financial discussions about the potential costs of breast reconstruction seldom occurred in this national cohort. Given the reported preference and unmet need for financial discussions by a majority of women, better cost transparency and communication is needed. Article published online: 19 January 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

surgery
Financial Toxicity Screening Preferences in Patients With Breast Cancer

Laila A Gharzai,Yingzhe Alex Liu,Zequn Sun,Leila J Mady,Michelle Mohn,Alexis Larson,Sheetal Kircher,Betina Yanez,Ruth C Carlos,John Pottow,Reshma Jagsi,Gelareh Sadigh

DOI: https://doi.org/10.1200/OP.24.00415

2024-09-17

Abstract:Purpose: Financial toxicity is an important issue in cancer that affects quality of life and treatment adherence. Screening can identify patients at risk but consensus on appropriate timing or methods is lacking. Methods: We sent an anonymous survey to e-mail subscribers of a nationwide breast cancer-specific philanthropic organization in July 2023 asking about financial toxicity screening preferences. Frequencies, percentages, and medians were calculated for categorical and continuous variables. Results: Of 5,774 potential participants, 738 respondents with a confirmed cancer diagnosis participated (12.7% response rate). Participants were 93% female (n = 690), had a median age of 50 years (IQR, 44-57), were 57% non-Hispanic White (n = 418), 20% Black/African-American (n = 149), 9.2% Hispanic (n = 68). 93% confirmed a breast cancer diagnosis (n = 689), and 54% were currently undergoing treatment (n = 400). Most indicated not being asked about financial stressors by (58%, n = 425) and not receiving assistance from their care team (68%, n = 498). Most preferred for providers to reach out regarding financial needs (83%, n = 615). Most wished for these discussions to take place early (when first diagnosed [45%, n = 334] or when treatment selected [37%, n = 275]) and to be asked frequently (each appointment [42%, n = 312] or once per month [36%, n = 268]). Participants felt most comfortable discussing financial needs with a social worker or patient/financial navigator (92%, n = 679), in person (75%, n = 553), or via telephone (65%, n = 479). Conclusion: Patients in this sample primarily consisting of women with breast cancer desired financial screening to occur early, often, and to be initiated by their providers. Patient preferences can inform optimal implementation of financial toxicity screening practices. Continued work refining best practices for financial toxicity screening should incorporate these patient preferences.
Breast cancer treatment receipt and the role of financial stress, health literacy, and numeracy among diverse breast cancer survivors

Ashley Odai-Afotey,Ruth I Lederman,Naomi Y Ko,Haley Gagnon,Tsion Fikre,Daniel A Gundersen,Anna C Revette,Dawn L Hershman,Katherine D Crew,Nancy L Keating,Rachel A Freedman

DOI: https://doi.org/10.1007/s10549-023-06960-w

Abstract:Purpose: Disparities in breast cancer treatment for low-income and minority women are well documented. We examined economic hardship, health literacy, and numeracy and whether these factors were associated with differences in receipt of recommended treatment among breast cancer survivors. Methods: During 2018-2020, we surveyed adult women diagnosed with stage I-III breast cancer between 2013 and 2017 and received care at three centers in Boston and New York. We inquired about treatment receipt and treatment decision-making. We used Chi-squared and Fisher's exact tests to examine associations between financial strain, health literacy, numeracy (using validated measures), and treatment receipt by race and ethnicity. Results: The 296 participants studied were 60.1% Non-Hispanic (NH) White, 25.0% NH Black, and 14.9% Hispanic; NH Black and Hispanic women had lower health literacy and numeracy and reported more financial concerns. Overall, 21 (7.1%) women declined at least one component of recommended therapy, without differences by race and ethnicity. Those not initiating recommended treatment(s) reported more worry about paying large medical bills (52.4% vs. 27.1%), worse household finances since diagnosis (42.9% vs. 22.2%), and more uninsurance before diagnosis (9.5% vs. 1.5%); all P < .05. No differences in treatment receipt by health literacy or numeracy were observed. Conclusion: In this diverse population of breast cancer survivors, rates of treatment initiation were high. Worry about paying medical bills and financial strain were frequent, especially among non-White participants. Although we observed associations of financial strain with treatment initiation, because few women declined treatments, understanding the scope of impact is limited. Our results highlight the importance of assessments of resource needs and allocation of support for breast cancer survivors. Novelty of this work includes the granular measures of financial strain and inclusion of health literacy and numeracy.
Interventions to alleviate financial toxicity among patients with cancer: A systematic review.

Asad Arastu,Andrew Hamilton,Emerson Yu-sheng Chen

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.e18841

IF: 45.3

2021-05-20

Journal of Clinical Oncology

Abstract:e18841 Background: Financial toxicity (FT) has become a recognized side effect associated with cancer diagnosis and treatment; however, there is little data on what interventions have proven to be effective at mitigating the financial burden patients might face. Methods: A systematic review following the Preferred Reporting Items for Systematic Reviews and Met-Analysis (PRISMA) guidelines was conducted in MEDLINE, Embase, and PsycInfo. Broad terminology to capture FT and all possible interventions was used to identify articles published through June 25, 2020 in MEDLINE and July 31, 2020 in Embase and PsycInfo. We excluded systematic reviews, studies not conducted in the United States, with non-adult participants, or those that did not examine an intervention to directly alleviate FT. Two independent reviewers (AA and EYC) reviewed all abstracts to identify which articles met inclusion criteria. An inductive approach was used to thematically categorize unique intervention strategies. Results: A total of 1126 abstracts were identified from the initial search strategy, and 9 met final inclusion criteria. Across these studies, 12 distinct strategies were reported in 27 unique occurrences. They were mapped into four broad domains: 1) patient assistance programs (PAPs) through pharmaceutical company and/or charity sponsored programs, 2) financial navigators who provide counseling and community resources, 3) direct coverage through free medications or payments, and 4) indirect coverage for related services (e.g. transportation). Direct coverage was most commonly proposed, 15/27 (56%) of interventions, followed by PAPs 5/27 (18%), financial navigators 4/27 (15%), and indirect costs 3/27 (11%). These interventions led to outcomes including: cost savings to patients in 5/9 studies (56%), alleviated fears surrounding cost of treatment in 2/9 (22%), earlier medication fills in 1/9 (11%), and decreased anxiety on a self-reported Likert scale in 1/9 (11%). Conclusions: While potential solutions to FT from cancer care remain unclear, this systematic review demonstrates that particular implemented strategies have lessened patient expenses, improved therapy adherence, or helped patients live better. Additional resources could help equip providers and institutions on how to use existing infrastructure (PAPs) or how to deploy additional workforce to diminish FT.

oncology
Klausner follows own advice at NCI

E. Marshall

DOI: https://doi.org/10.1126/SCIENCE.7638609

IF: 56.9

1995-08-18

Science

Abstract:

Extending tranSMART for Meta-Analysis of Genomic Data Across Trials

Short-term and long-term financial toxicity from breast cancer treatment: a qualitative study

Financial toxicity experienced by patients with breast cancer-related lymphedema: a systematic review

Patient-Reported Financial Burden of Treatment for Colon or Rectal Cancer

The social and economic toll of cancer survivorship: a complex web of financial sacrifice

Self-Reported Risk Factors for Financial Distress and Attitudes Regarding Cost Discussions in Cancer Care: A Single-Institution Cross-Sectional Pilot Study of Breast Reconstruction Recipients

Ornstein theory

Patient and family financial burden associated with cancer treatment in Canada: a national study

Financial cost of lymphedema borne by women with breast cancer

Patient‐reported persistent lymphedema and peripheral neuropathy among long‐term breast cancer survivors in the Carolina Breast Cancer Study

Diagnostic impression cytology for external eye disease.

Antimicrobial resistance of Staphylococcus pseudintermedius.

Logistic burdens of cancer care: A qualitative study

Predictors of financial difficulties and work modifications among cancer survivors in the United States

Patient Perceived Financial Burden in Haematological Malignancies: A Systematic Review.

The need for online information on the economic consequences of cancer diagnosis, treatment, and survivorship

Financial Toxicity in Breast Reconstruction: The Role of the Surgeon-Patient Cost-of-Care Discussion

Financial Toxicity Screening Preferences in Patients With Breast Cancer

Breast cancer treatment receipt and the role of financial stress, health literacy, and numeracy among diverse breast cancer survivors

Interventions to alleviate financial toxicity among patients with cancer: A systematic review.

Klausner follows own advice at NCI